By Mill Chart
Last update: Sep 26, 2023
Uncover the potential of NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), a growth stock that our stock screener found to be reasonably priced. NYSE:NVO is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive valuation. We'll examine each aspect in detail.
To evaluate a stock's growth potential, ChartMill utilizes a Growth Rating on a scale of 0 to 10. This comprehensive assessment considers various growth aspects, including historical and estimated EPS and revenue growth. NYSE:NVO has achieved a 7 out of 10:
An integral part of ChartMill's stock analysis is the Valuation Rating, which spans from 0 to 10. This rating evaluates diverse valuation factors, including price to earnings and cash flows, while considering the stock's profitability and growth. NYSE:NVO has received a 7 out of 10:
ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NYSE:NVO scores a 7 out of 10:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NYSE:NVO has achieved a 9:
Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.
For an up to date full fundamental analysis you can check the fundamental report of NVO
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
NOVO-NORDISK A/S-SPONS ADR
NYSE:NVO (11/29/2023, 7:17:05 PM)After market: 101.7 -0.3 (-0.29%)
Real-world data showed some real-world advantages for Ozempic's top rival.
The study examined health care records for more than 41,000 people.
A real-world study finds Eli Lilly&#39;s (LLY) weight loss drug tirzepatide is three times more effective than Novo Nordisk&#39;s (NVO) rival drug, semaglutide. Read more here.
The stock market is such a well-oiled, wealth-generating machine that investors can start with just $100 to buy these no-brainer stocks.
Financial investor Niall Gallagher halves his fund&#39;s ownership in Novo Nordisk (NVO) due to hype surrounding weight loss drugs. Read more here.
An upcoming mid-stage readout may not spark a trend reversal in the big pharma's shares.
Four of the stocks tripped up after earnings, but quickly bounced back.
The drug is on track to cause massive competitive shifts in the healthcare sector.
The stock market is poised to rally at the year end as multiple positive factors conspire to push certain sectors higher.
Novo Nordisk plans to introduce its weight-loss drug, Wegovy, in Asia, starting with Japan.
While growth is established for NYSE:NVO, the stock's valuation remains reasonable.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Reveals Intriguing Technical Aspects. Here's What You Need to Know.